TAK‐632

News alerts, weekly reports and conference planners

Company:

Takeda

Drug class:

pan-RAF inhibitor, RIPK1 inhibitor, RIPK3 inhibitor

Related drugs:

BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	TAK‐632 Sensitive: D – Preclinical TAK‐632 Sensitive : D	TAK‐632 Sensitive: D – Preclinical TAK‐632 Sensitive : D
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	PLX4720 + TAK‐632 Sensitive: D – Preclinical PLX4720 + TAK‐632 Sensitive : D	PLX4720 + TAK‐632 Sensitive: D – Preclinical PLX4720 + TAK‐632 Sensitive : D
BRAF V600E	Thyroid Gland Carcinoma	BRAF V600E	Thyroid Gland Carcinoma	TAK‐632 Sensitive: D – Preclinical TAK‐632 Sensitive : D	TAK‐632 Sensitive: D – Preclinical TAK‐632 Sensitive : D

Associations
(3)